| Dhaliwal, Sandeep |
| Completed | 3 | 407 | Europe, Canada, US, RoW | Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir | Eiger BioPharmaceuticals | Hepatitis Delta Virus | 10/22 | 03/23 | | |
| Recruiting | 2 | 42 | US | Sulfasalazine, Azulfidine, Placebo | Brigham and Women's Hospital | Primary Sclerosing Cholangitis | 09/24 | 11/24 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
| Active, not recruiting | 1/2 | 4 | Europe, US | VTX-801 | Vivet Therapeutics SAS | Wilson's Disease | 12/24 | 06/29 | | |
EXPLORER, NCT04165343: Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on |
|
|
| Completed | N/A | 81 | US | Positron Emission Tomography (PET) on EXPLORER, PET Scan, Magnetic Resonance Imaging, MRI, Echocardiogram and Electrocardiogram, Echo and EKG or ECG, Blood test, Lab test | University of California, Davis | Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) | 05/23 | 05/23 | | |
NCT03560037: Use of a Distal Colonoscope Attachment to Increase Detection of Sessile Serrated Adenomas |
|
|
| Completed | N/A | 427 | US | Endocuff Vision Assisted Colonoscopy | University of California, Davis | Sessile Serrated Adenoma | 12/23 | 12/23 | | |
NCT02754037: Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study |
|
|
| Active, not recruiting | N/A | 120 | US | Fluorodeoxyglucose (FDG) positron emission tomography (PET), Magnetic resonance imaging (MRI), Magnetic resonance proton density fat fraction (MR-PDFF), Magnetic resonance elastography (MRE), PET Explorer | University of California, Davis, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) | 06/25 | 06/25 | | |
| Recruiting | N/A | 10000 | Europe, US | | Target PharmaSolutions, Inc. | Hepatocellular Cancer | 10/25 | 10/25 | | |
TARGET-IBD, NCT03251118: A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease |
|
|
| Recruiting | N/A | 15000 | US | | Target PharmaSolutions, Inc. | Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis | 10/25 | 10/25 | | |
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection |
|
|
| Recruiting | N/A | 5000 | Canada, US | All approved therapies for the treatment of Chronic Hepatitis B (CHB) | Target PharmaSolutions, Inc. | Hepatitis B, Hepatitis, Liver Diseases | 01/26 | 01/26 | | |
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) |
|
|
| Recruiting | N/A | 15000 | Europe, US | | Target PharmaSolutions, Inc. | Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | 07/36 | 07/36 | | |
| Johnson, Cole |
| No trials found |
